New HIV vaccine strategy aims to trigger powerful antibodies
NCT ID NCT05471076
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing two experimental HIV vaccines in 52 healthy adults without HIV. The goal is to see if the vaccines are safe and can stimulate the immune system to produce broadly neutralizing antibodies, which are key to fighting many HIV strains. Participants receive different doses of the vaccines or a placebo, and researchers will monitor side effects and immune responses over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Experimental HIV vaccines (426c.Mod.Core-C4b and BG505 SOSIP.GT1.1 gp140) with an adjuvant (3M-052-AF + alum)
What this could lead to
If successful, this could point toward a vaccine that trains the immune system to make broadly neutralizing antibodies against many HIV strains.
What could go wrong
This is a very early phase 1 trial with only 52 participants, focused on safety and immune response, not on preventing HIV. Many vaccine candidates fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama CRS
Birmingham, Alabama, 35222, United States
-
Bridge HIV CRS
San Francisco, California, 94102, United States
-
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
Boston, Massachusetts, 02115-6110, United States
-
Columbia P&S CRS
New York, New York, 10032, United States
-
Seattle Vaccine and Prevention CRS
Seattle, Washington, 98104, United States
-
The Ponce de Leon Center CRS
Atlanta, Georgia, 30308-2012, United States